Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancer surgery is necessary and life-saving. However, the majority of patients develop postoperative recurrence and metastasis, which are the main causes of cancer-related deaths. The postoperative stress response encompasses a broad set of physiological changes that have evolved to safeguard the host following major tissue trauma. These stress responses, however, intersect with cellular mediators and signaling pathways that contribute to cancer proliferation. MAIN: Previous descriptive and emerging mechanistic studies suggest that the surgery-induced prometastatic effect is linked to impairment of both innate and adaptive immunity. Existing studies that combine surgery and immunotherapies have revealed that this combination strategy is not straightforward and patients have experienced both therapeutic benefit and drawbacks. This review will specifically assess the immunological pathways that are disrupted by oncologic surgical stress and provide suggestions for rationally combining cancer surgery with immunotherapies to improve immune and treatment outcomes. SHORT CONCLUSION: Given the prevalence of surgery as frontline therapy for solid cancers, the emerging data on postoperative immunosuppression and the rapid development of immunotherapy for oncologic treatment, we believe that future targeted studies of perioperative immunotherapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“neoadjuvant ICIs can induce a more robust immune response than adjuvant ICIs, given the immunosuppressive systemic effects of invasive surgery125–127.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [127]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Enhanced DC function leading to increased CD8 T-cell priming and tumor infiltration was suggested to be the underlying mechanism of combination therapy [99].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“thetaiotaomicron influencing antitumor response through IL-2 dependent Th1 immunity, while simultaneously limiting anti-CTLA-4-mediated intestinal adverse effects [100] (Fig.”
BackgroundLanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099 · cited 1×
“In addition, rapid expansion of mutationassociated, neoantigen-specific T-cells was observed as early as 2 to 4 weeks following initial nivolumab administration demonstrating the additional benefit of neoadjuvant treatment [66].”
BackgroundLanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Gross, K. S., Brandner, D. D., Martinez, L. A., Olive, M. F., Meisel, R. L., & Mermelstein, P. G. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162755 · Cited by 1,609
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Mirnezami, A., Mirnezami, R., Chandrakumaran, K., Sasapu, K., Sagar, P., & Finan, P. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182128929 · Cited by 875
Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock
Van Amersfoort, E. S., Van Berkel, T. J. C., & Kuiper, J. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.3.379-414.2003 · Cited by 750
Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y., & Hodin, R. A. (2002) · The Journal of Nutrition · doi:10.1093/jn/132.5.1012 · Cited by 544 · cited 1×
“Specific to CRC surgery, additional perioperative factors such as changes in the gut microbiome of the patient leading to depletion of short-chain fatty acids [95] and the development of anastomotic complications have been associated with increased risk of local tumor recur-”
Background
Research works printed but not linked: 1
- Bohle W, Schlag P, Liebrich W, Hohenberger P, Manasterski M, Moiller P, et al. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus. Cancer Immunol Immunother. 1990;66:1517–23.
Cited by
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
“In addition, as discussed, neoadjuvant ICIs can induce a more robust immune response than adjuvant ICIs, given the immunosuppressive systemic effects of invasive surgery 125–127 .”
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C., Xia, B.-R., Zhang, Z.-C., Zhang, Y.-J., Lou, G., & Jin, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 350
“Neoadjuvant immunotherapy has demonstrated remarkable efficacy in cancer patients as compared to surgery followed by adjuvant immunotherapy, as the adverse effects of surgeryinduced metastasis are associated with innate and adaptive immunity damage (184) (Figure 3B).”
BackgroundSurgical stress and cancer progression: the twisted tango
Chen, Z., Zhang, P., Xu, Y., Yan, J., Liu, Z., Lau, W. B., Lau, B., Li, Y., Zhao, X., Wei, Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1058-3 · Cited by 223
“pletely, indicating the potential of immunotherapy in surgical stress and tumor therapy [148].”
BackgroundSurgical trauma‐induced immunosuppression in cancer: Recent advances and the potential therapies
Tang, F., Tie, Y., Tu, C., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.24 · Cited by 206
Mountzios, G., Remon, J., Hendriks, L. E. L., García-Campelo, R., Rolfo, C., Van Schil, P., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 199
Metadata
- Authors
- Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H.
- Affiliations
- Université de Sherbrooke (CA)
- Corresponding author
- Tai, Lee-Hwa
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2018-09-03
- Volume
- 6
- Issue
- 1
- Pages
- 86-86
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC6122574
- OpenAlex
- W2888941300
- Cited by
- 192
- References
- 102
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 23 · 2023: 38 · 2022: 33 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 1
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Cancer Research Society
- Natural Sciences and Engineering Research Council of Canada
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- cancer surgery, immunotherapy, perioperative immunotherapy, postoperative immunosuppression, surgical stress response, metastasis, postoperative recurrence, innate immunity, adaptive immunity
- MeSH terms
- Animals, Combined Modality Therapy, Humans, Immunosuppression Therapy, Immunotherapy, Neoplasms, Treatment Outcome, Disease Management, Cancer Vaccines, Perioperative Care, Molecular Targeted Therapy, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. https://app.cochat.ai/papers/10.1186/s40425-018-0398-7
- The paper
- Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H. (2018). Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-018-0398-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.